- Home
- CRIS vs TENX Comparison
CRIS vs TENX Comparison
Compare CRIS & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRIS
- TENX
- Stock Information
- Founded
- CRIS 2000
- TENX 1967
- Country
- CRIS United States
- TENX United States
- Employees
- CRIS N/A
- TENX N/A
- Industry
- CRIS Biotechnology: Biological Products (No Diagnostic Substances)
- TENX Biotechnology: Pharmaceutical Preparations
- Sector
- CRIS Health Care
- TENX Health Care
- Exchange
- CRIS Nasdaq
- TENX Nasdaq
- Market Cap
- CRIS 22.9M
- TENX 27.3M
- IPO Year
- CRIS 2000
- TENX N/A
- Fundamental
- Price
- CRIS $1.67
- TENX $6.25
- Analyst Decision
- CRIS Strong Buy
- TENX Strong Buy
- Analyst Count
- CRIS 2
- TENX 4
- Target Price
- CRIS $16.50
- TENX $16.67
- AVG Volume (30 Days)
- CRIS 76.7K
- TENX 47.8K
- Earning Date
- CRIS 11-13-2025
- TENX 11-12-2025
- Dividend Yield
- CRIS N/A
- TENX N/A
- EPS Growth
- CRIS N/A
- TENX N/A
- EPS
- CRIS N/A
- TENX N/A
- Revenue
- CRIS $11,405,000.00
- TENX N/A
- Revenue This Year
- CRIS $1.41
- TENX N/A
- Revenue Next Year
- CRIS $7.46
- TENX N/A
- P/E Ratio
- CRIS N/A
- TENX N/A
- Revenue Growth
- CRIS 12.24
- TENX N/A
- 52 Week Low
- CRIS $1.02
- TENX $3.25
- 52 Week High
- CRIS $6.44
- TENX $7.89
- Technical
- Relative Strength Index (RSI)
- CRIS 45.61
- TENX 64.21
- Support Level
- CRIS $1.63
- TENX $6.02
- Resistance Level
- CRIS $1.95
- TENX $6.25
- Average True Range (ATR)
- CRIS 0.15
- TENX 0.15
- MACD
- CRIS 0.00
- TENX 0.03
- Stochastic Oscillator
- CRIS 17.65
- TENX 58.33
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.